文献速递青光眼

全身药物使用与青光眼及眼压的关联:欧洲眼科流行病学联盟研究

Association of Systemic Medication Use with Glaucoma and Intraocular Pressure: The European Eye Epidemiology Consortium.
PubMed 文献 · Ophthalmology · 2023-05-06

该研究为欧洲眼科流行病学联盟11项人群队列研究的Meta分析,纳入青光眼分析143240人、眼压分析47177人,评估4类全身药物与青光眼患病率及眼压的关联。结果显示钙通道阻滞剂使用与青光眼患病率较高相关(OR 1.23),全身β受体阻滞剂使用与较低眼压相关(β系数-0.33 mmHg)。

要点

  • 钙通道阻滞剂使用与青光眼患病率较高相关(OR 1.23,95%CI 1.08-1.39)。
  • 全身β受体阻滞剂使用与较低眼压相关(β系数-0.33 mmHg,95%CI -0.57至-0.08 mmHg)。
  • 其他降压药、降脂药、抗抑郁药及降糖药与青光眼或眼压无显著关联。

核心结论

  • 研究发现使用钙通道阻滞剂与青光眼患病率之间存在潜在有害关联。
  • 研究观察并量化了全身β受体阻滞剂使用与较低眼压的关联。
  • 鉴于青光眼患者常使用全身降压药,上述两项发现可能均具有重要意义。
  • 确定钙通道阻滞剂关联的因果性应作为研究优先事项。

研究设计与样本

  • 研究设计为欧洲眼科流行病学联盟11项人群队列研究的Meta分析。
  • 青光眼分析纳入143240名参与者,眼压分析纳入47177名参与者。
  • 研究检查4类全身药物(降压药、降脂药、抗抑郁药、降糖药)与青光眼患病率及眼压的关联。
  • 各研究多变量回归分析结果采用随机效应Meta分析进行合并。
  • 降糖药关联仅在糖尿病患者中检查。

主要发现

  • 在最大调整多变量模型Meta分析中,使用钙通道阻滞剂与青光眼患病率较高相关(OR 1.23;95%CI 1.08至1.39)。
  • 具有直接心脏效应的钙通道阻滞剂单药治疗与青光眼关联更强(OR 1.96;95%CI 1.23至3.12)。
  • 全身β受体阻滞剂使用与较低眼压相关(β系数-0.33 mmHg;95%CI -0.57至-0.08 mmHg)。
  • 选择性全身β受体阻滞剂单药治疗(β系数-0.45 mmHg;95%CI -0.74至-0.16 mmHg)和非选择性全身β受体阻滞剂单药治疗(β系数-0.54 mmHg;95%CI -0.94至-0.15 mmHg)均与较低眼压相关。
  • 高效利尿剂使用与较低眼压存在提示性关联(β系数-0.30 mmHg;95%CI -0.47至-0.14 mmHg),但单药治疗时无此关联。

关键数值与推荐

  • 钙通道阻滞剂使用与青光眼患病率较高相关(OR 1.23;95%CI 1.08至1.39)。
  • 具有直接心脏效应的钙通道阻滞剂单药治疗与青光眼患病率较高相关(OR 1.96;95%CI 1.23至3.12)。
  • 全身β受体阻滞剂使用与较低眼压相关(β系数-0.33 mmHg;95%CI -0.57至-0.08 mmHg)。
  • 选择性全身β受体阻滞剂单药治疗与较低眼压相关(β系数-0.45 mmHg;95%CI -0.74至-0.16 mmHg)。
  • 非选择性全身β受体阻滞剂单药治疗与较低眼压相关(β系数-0.54 mmHg;95%CI -0.94至-0.15 mmHg)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the association of commonly used systemic medications with glaucoma and intraocular pressure (IOP) in the European population. DESIGN: Meta-analysis of 11 population-based cohort studies of the European Eye Epidemiology Consortium. PARTICIPANTS: The glaucoma analyses included 143 240 participants and the IOP analyses included 47 177 participants. METHODS: We examined associations of 4 categories of systemic medications-antihypertensive medications (β-blockers, diuretics, calcium channel blockers [CCBs], α-agonists, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers), lipid-lowering medications, antidepressants, and antidiabetic medications-with glaucoma prevalence and IOP. Glaucoma ascertainment and IOP measurement method were according to individual study protocols. Results of multivariable regression analyses of each study were pooled using random effects meta-analyses. Associations with antidiabetic medications were examined in participants with diabetes only. MAIN OUTCOME MEASURES: Glaucoma prevalence and IOP. RESULTS: In the meta-analyses of our maximally adjusted multivariable models, use of CCBs was associated with a higher prevalence of glaucoma (odds ratio [OR], 1.23; 95% confidence interval [CI], 1.08 to 1.39). This association was stronger for monotherapy of CCBs with direct cardiac effects (OR, 1.96; 95% CI, 1.23 to 3.12). No other antihypertensive medications, lipid-lowering medications, antidepressants, or antidiabetic medications were associated with glaucoma. Use of systemic β-blockers was associated with a lower IOP (β coefficient, -0.33 mmHg; 95% CI, -0.57 to -0.08 mmHg). Monotherapy of both selective systemic β-blockers (β coefficient, -0.45 mmHg; 95% CI -0.74 to -0.16 mmHg) and nonselective systemic β-blockers (β coefficient, -0.54 mmHg; 95% CI, -0.94 to -0.15 mmHg) was associated with lower IOP. A suggestive association was found between use of high-ceiling diuretics and lower IOP (β coefficient, -0.30 mmHg; 95% CI, -0.47 to -0.14 mmHg) but not when used as monotherapy. No other antihypertensive medications, lipid-lowering medications, antidepressants, or antidiabetic medications were associated with IOP. CONCLUSIONS: We identified a potentially harmful association between use of CCBs and glaucoma prevalence. Additionally, we observed and quantified the association of lower IOP with systemic β-blocker use. Both findings potentially are important, given that patients with glaucoma frequently use systemic antihypertensive medications. Determining causality of the CCB association should be a research priority. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Vergroesen JE, Schuster AK, Stuart KV, et al. Association of Systemic Medication Use with Glaucoma and Intraocular Pressure: The European Eye Epidemiology Consortium. Ophthalmology. 2023. PMID: 37150298. doi:10.1016/j.ophtha.2023.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。